Skip to main content

Table 4 Drug-related adverse events of S-1 administered by 2 schedules

From: Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial

 

Arm A (n = 38)

Arm B (n = 40)

p

G1/2

G3

G1/2

G3

n

(%)

n

(%)

n

(%)

n

(%)

Hematological

31

(82)

1

(3)

26

(65)

0

(0)

0.10

 Neutropenia

9

(24)

1

(3)

8

(20)

0

(0)

0.36

 Thrombocytopenia

12

(32)

0

(0)

11

(28)

0

(0)

0.81

 Anemia

27

(71)

0

(0)

23

(58)

0

(0)

0.23

 Leukopenia

17

(45)

0

(0)

15

(38)

0

(0)

0.65

Non-hematological

35

(92)

3

(8)

35

(88)

2

(5)

0.21

 Elevation of Bilirubin

24

(63)

2

(5)

15

(38)

0

(0)

0.01

 Elevation of ALP

16

(42)

0

(0)

6

(15)

0

(0)

<0.01

 Elevation of AST

16

(42)

0

(0)

5

(13)

0

(0)

<0.01

 Elevation of ALT

15

(39)

0

(0)

3

(8)

0

(0)

0.01

 Rash

6

(16)

1

(3)

9

(23)

0

(0)

0.45

 Anorexia

14

(37)

0

(0)

12

(30)

2

(5)

0.34

 Nausea

15

(39)

0

(0)

14

(35)

1

(3)

0.59

 Elevation of BUN

1

(3)

0

(0)

1

(3)

0

(0)

1.00

 Elevation of Creatinin

1

(3)

0

(0)

5

(13)

0

(0)

0.20

 Pigmentation

12

(32)

0

(0)

15

(38)

0

(0)

0.63

 Diarrhea

12

(32)

0

(0)

9

(23)

0

(0)

0.44

 General fatigue

6

(16)

0

(0)

10

(25)

0

(0)

0.40

 Decline in PS

4

(11)

0

(0)

6

(15)

0

(0)

0.74

 Vomiting

4

(11)

0

(0)

3

(8)

0

(0)

0.71

 Aphthous stomatitis

3

(8)

0

(0)

6

(15)

0

(0)

0.48

 Nervous system disorder

2

(5)

0

(0)

1

(3)

0

(0)

0.61

 Edema

2

(5)

0

(0)

2

(5)

0

(0)

1.00

 Infection

1

(3)

0

(0)

1

(3)

0

(0)

1.00

 Others

6*

(16)

0

(0)

11**

(28)

0

(0)

0.19

Total

34

(89)

4

(11)

37

(93)

2

(5)

0.42

  1. Arm A: 4 weeks of oral S-1 and a 2-week rest over 12 months; arm B: 2 weeks of S-1 and a 1-week rest over 12 months; ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine transaminase, BUN blood urea nitrogen, PS performance status; * = dizziness (1), urticaria (1), lacrimation (1), ileus (1), finger cyanosis (1), nasal bleeding (1) and dyspnea (1); ** = nasal bleeding (4), taste disorder (2), dizziness (1), fever (1), dry skin (1), finger bleeding (1), lacrimation (1), cutaneous pruritus (1), blurred vision (1); p values were calculated with the use of the chi-square test. The total number of patients of each arm was used as a denominator when calculating category-specific percentages in the table
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us